| 2025 | Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)
| ESMO OPEN |
| 2025 | GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours | BRITISH JOURNAL OF CANCER |
| 2025 | Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
| BMC CANCER |
| 2025 | Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer | ESMO OPEN |
| 2025 | Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study | LANCET ONCOLOGY |
| 2025 | Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer
| JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE |
| 2024 | Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
| GYNECOLOGIC ONCOLOGY |
| 2024 | Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer | CANCER LETTERS |
| 2024 | Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers
| BMC MEDICINE |
| 2024 | Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial
| NATURE MEDICINE |
| 2024 | A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
| NPJ BREAST CANCER |
| 2024 | A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2023 | Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
| CANCER RESEARCH AND TREATMENT |
| 2023 | Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA
| NATURE COMMUNICATIONS |
| 2023 | Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
| CANCER RESEARCH AND TREATMENT |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
| 2022 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| 2022 | Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
| BREAST |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
| INTERNATIONAL JOURNAL OF CANCER |
| 2021 | Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
| CANCER RESEARCH AND TREATMENT |
| 2021 | Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective | ANNALS OF SURGERY |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2021 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study | EUROPEAN JOURNAL OF CANCER |
| 2021 | Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2020 | Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
| CANCERS |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis | BREAST CARE |
| 2020 | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
| CANCER RESEARCH AND TREATMENT |
| 2020 | Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial
| BMC CARDIOVASCULAR DISORDERS |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study | SUPPORTIVE CARE IN CANCER |
| 2019 | Involved-field radiation therapy for selected cases of recurrent ovarian cancer
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2019 | Effect of primary tumor resection on overall survival in patients with stage IV breast cancer | BREAST JOURNAL |
| 2019 | A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
| CANCER RESEARCH AND TREATMENT |
| 2018 | External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence
| Radiation Oncology Journal |
| 2018 | Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma | VIRCHOWS ARCHIV |
| 2018 | Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
| CANCER RESEARCH AND TREATMENT |
| 2018 | The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control | CANCER NURSING |
| 2018 | CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
| ONCOTARGET |
| 2017 | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2017 | Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
| ANNALS OF SURGICAL TREATMENT AND RESEARCH |
http://orcid.org/0000-0001-9167-8682
(24483766500)
